Innoviva (INVA) Expected to Announce Quarterly Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $102.6240 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Innoviva Stock Down 1.1%

INVA opened at $23.39 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 14.12 and a quick ratio of 13.33. Innoviva has a 12 month low of $16.52 and a 12 month high of $24.01. The stock has a market capitalization of $1.75 billion, a P/E ratio of 17.07 and a beta of 0.44. The business has a 50 day simple moving average of $20.52 and a 200-day simple moving average of $19.94.

Analyst Ratings Changes

INVA has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of Innoviva in a research report on Tuesday, February 17th. They set a “buy” rating and a $35.00 target price on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. HC Wainwright increased their target price on shares of Innoviva from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald lifted their price target on shares of Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Zacks Research cut Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Innoviva presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.17.

Hedge Funds Weigh In On Innoviva

A number of institutional investors have recently made changes to their positions in INVA. Royal Bank of Canada boosted its stake in shares of Innoviva by 81.1% during the first quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock valued at $389,000 after acquiring an additional 9,639 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Innoviva by 17.8% in the 1st quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock valued at $3,036,000 after purchasing an additional 25,317 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Innoviva by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 1,392 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Innoviva during the first quarter worth about $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Innoviva by 21.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock valued at $3,102,000 after buying an additional 30,792 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.